Management of Proteinuria

Introduction to Proteinuria

Proteinuria is a cardinal feature of diabetic kidney disease, characterized by the presence of excess proteins in the urine, which can be caused by various factors including diabetic nephropathy, and can be quantified by measuring albumin/creatinine ratio (ACR) in a laboratory 1, 2

The treatment target for proteinuria is less than 0.5-0.7 g/24 hours by 12 months, defined as a complete clinical response, and at least 50% reduction in proteinuria by 6 months, defined as a partial clinical response 3
For patients with nephrotic-range proteinuria, the timeframes for achieving these targets may be extended by 6-12 months 3

The American Journal of Kidney Diseases recommends a target dietary protein intake of 0.8 g/kg body weight per day to reduce albuminuria and stabilize kidney function, while excessive protein restriction should be avoided, with protein intake not less than 0.8 g/kg/day, as there's no conclusive evidence of additional benefit, and higher protein intake (>1.3 g/kg/day) is associated with increased proteinuria and decreased renal function 1, 4, 5, 6
A diet high in vegetables, fruits, whole grains, fiber, legumes, and plant-based proteins is recommended, along with moderate-intensity physical activity for at least 150 minutes per week, and weight normalization if overweight or obese, as recommended by the American Heart Association, the Academy of Nutrition and Dietetics, and the American College of Sports Medicine 7, 8, 9, 6

Limit sodium intake to less than 2 g/day to help control blood pressure, with a recommended blood pressure target of:

Proteinuria Level	Target Blood Pressure
>1 g/day	<125/75 mmHg
<1 g/day	<130/80 mmHg
Pediatric patients	≤50th percentile for age, sex, and height

ACE inhibitor or ARB therapy should be initiated even in normotensive diabetic patients with albuminuria, according to the American Journal of Kidney Diseases, with the goal of reducing proteinuria to <1 g/day or as low as possible, and monitoring serum creatinine and potassium within 1-2 weeks after initiating or increasing dose, expecting a modest increase in serum creatinine (up to 30%) which is acceptable, and discontinue if kidney function continues to worsen or if refractory hyperkalemia develops, as recommended by the National Kidney Foundation and the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 2, 13, 7
Dual RAS blockade (ACE inhibitor + ARB) may provide additional proteinuria reduction, but its use should be cautious due to increased risk of hyperkalemia and acute kidney injury, as reported by the Kidney International guidelines and National Kidney Foundation 2, 13
Non-dihydropyridine CCBs, such as diltiazem and verapamil, may have antiproteinuric effects, while amlodipine should generally be avoided in patients with glomerular hypertension, as reported by the American Journal of Kidney Diseases and Journal of the American Society of Nephrology 14, 15

Monitor albumin:creatinine ratio every 3-6 months to assess treatment response, with a goal to reduce proteinuria to <1 g/day or as low as possible, as recommended by the Kidney International guideline, and monitor blood pressure at every clinic visit, and assess for medication adherence at each visit 16, 7
For elderly patients with multiple comorbidities, less stringent HbA1c targets (around 7.5-8.0%) may be appropriate, as suggested by Kidney International, and HbA1c should be monitored quarterly until stable, then twice yearly, as recommended by Kidney International 5, 17

Refer patients to nephrology if they have persistent proteinuria >1g/day, GFR <30 mL/min/1.73 m², abrupt sustained decrease in eGFR >20%, inability to tolerate renoprotective medications, uncertainty about diagnosis, or risk of kidney failure within 1 year is 10-20% or higher, as recommended by the American Journal of Kidney Diseases, and initiate discussion about modality of renal replacement therapy for patients with a GFR of 19 mL/min/1.73m², as recommended by the American Society of Nephrology 17, 18